Procto-Hemolan control

proctohemolan-tabletki-pack

Why use Procto-Hemolan control tablets?

Strenghtens and protects the veins

Procto-Hemolan control medicine contains diosmin, which increases the tension of veins and protects the blood vessels. It reduces the permeability of blood vessels and inflammation.

Prevents the relapse of hemorrhoids

Reduces the permeability of blood vessels, inflammation and small blood vessels’ susceptibility to rupture.

Full information about the product

Procto-Hemolan control, 20 tablets

Composition: one tablet contains 1000 mg of diosmin (diosminum).

Indications: symptomatic treatment in case of worsening of symptoms associated with varicose veins of the anus (hemorrhoids).

Dosage and method of administration: orally. Exacerbation of symptoms related to hemorrhoids: 3 tablets a day for 4 days, then 2 tablets per day for 3 consecutive days during meals.

Contraindications: This medicinal product should not be used in patients with hypersensitivity to the active substance or to any of the excipients.

Interactions with other drugs and other forms of interactions: no clinically signficant interactions with other drugs.

Pregnancy and lactation

Pregnancy: research conducted on animals does not indicate direct or indirect harmful effects on the pregnancy, the embryo (fetus) or parturition. In case of a vast need, the product can be prescribed to a pregnant woman.

Breastfeeding: do not use the medicinal product during breastfeeding due to the lack of data on penetration of the product into breast milk.

Side effects: side effects have been described with regard to the incidence rate according to the following convention: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥ 1/1 000, <1/100), rare (≥ 1/10 000, <1/1 000), very rare (<1/10 000). Disorders of the stomach and intestines. Rare: diarrhea, dyspepsia, nausea, vomiting. Nervous system disorders. Rare: dizziness, headache, malaise. Skin and subcutaneous tissue disorders. Rash, pruritus, urticaria. Observed side effects should not causa discontinuation of the therapy.

Marketing Authorisation Holder: Aflofarm Farmacja Polska Sp. z o.o.